Lucerne

A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration.

Study Type  : Interventional  (Clinical Trial)
Actual Enrollment  : 658 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
Actual Study Start Date  : March 11, 2019
Actual Primary Completion Date  : October 5, 2020
Actual Study Completion Date  : January 18, 2022

Related Publications

Our Affiliates